Poseida Therapeutics (STU:2RZ) 3-Year EBITDA Growth Rate : 29.40% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics 3-Year EBITDA Growth Rate?

Poseida Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.20.

During the past 3 years, the average EBITDA Per Share Growth Rate was 29.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Poseida Therapeutics was 29.50% per year. The lowest was -93.10% per year. And the median was 6.15% per year.

Competitive Comparison of Poseida Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Poseida Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poseida Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's 3-Year EBITDA Growth Rate falls into.

Poseida Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Poseida Therapeutics (STU:2RZ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Poseida Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (STU:2RZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PSTX:USA 2RZ:Germany

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics (STU:2RZ) Headlines

No Headlines